Injectable Skin Boosters: The Science Behind this New FDA-Approved Injectable Category
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we had the opportunity to learn about injectable skin boosters from Dr. Terrence Keaney, Founder and Director of SkinDC and Clinical Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences. In the constantly evolving landscape of aesthetic dermatology, new products and devices a …
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we had the opportunity to learn about injectable skin boosters from Dr. Terrence Keaney, Founder and Director of SkinDC and Clinical Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences. In the constantly evolving landscape of aesthetic dermatology, new products and devices a … 
Do implicit bias and race-compliance stereotyping impact clinical decision making in psoriasis? A feasibility study published in the February issue of the Journal of Drugs in Dermatology sought to answer this question.
To learn more about the key findings and takeaways, I interviewed one of the authors, Rithu Srikantha, MD, associate professor of dermatology at the Feinberg School of Medicine/N … 
What is the underlying infection in this neonate?
A. Syphilis
B. Leishmania
C. Chlamydia
D. Gonorrhea
E. Tuberculosis
To find out the correct answer and read the explanation, click here. … 
At the 2023 Skin of Color Update, Dr. David Ciocon, Director of Dermatologic Surgery, Mohs Micrographic Surgery (MMS) and Procedural Dermatology at the Montefiore Medical Center, Albert Einstein College of Medicine, provided a comprehensive exploration of MMS in patients with skin of color, with a focus on defining keratinocyte carcinoma and shedding light on disparities within this patient popula … 
Oxymetazoline is an adrenoreceptor agonist which is FDA-approved for dermatologic conditions including persistent facial erythema in rosacea and blepharoptosis. Functioning primarily as a vasoconstrictor with additional anti-inflammatory properties, oxymetazoline targets the sustained vasodilated state of cutaneous blood vessels in rosacea by inducing vasoconstriction and reducing the persistent f …